Scale-up is where good products fail

By Chris Storer, General Manager at JT Grosvenor

Every year, promising speciality chemical products across markets such as cleaning products, agriculture, animal care, garden care, and beyond fail – not because the formulations don’t deliver as intended, but because it can’t be manufactured reliably at a commercial scale.

A product can perform exceptionally well in development, meet a genuine market need, generate confidence within the technical team and deliver exactly what it was designed to do in the laboratory. Yet, none of that guarantees commercial success.

The defining test comes later, when the product must move beyond controlled trials and into repeatable, large-scale production. This is where momentum often turns into risk and many good products begin to come unstuck.

Scale-up is not simply a bigger batch

One of the biggest misconceptions in product development is that scale-up is simply a question of increasing volume. If a formulation performs well in a pilot batch, the assumption is that it should behave the same way in full production. In reality, this is where many development programmes go wrong.

Scale-up is not just an engineering exercise. It is a commercial systems challenge that brings together formulation, manufacturing, procurement, packaging, quality, logistics and supply chain planning. Success depends on whether the whole system can perform consistently, not just whether the chemistry works. A technically excellent product can still struggle commercially because the route to manufacture, filling, packaging and distribution was never designed with scale in mind.

As production volumes increase, the variables multiply.

Raw material availability changes. Mixing dynamics differ between pilot and production vessels. Equipment behaves differently, production schedules become tighter and commercial expectations around quality, cost and lead times all begin to merge. These are not unusual problems.

For example, we’ve seen formulations that remain perfectly stable during pilot production behave differently once mixing profiles and batch sizes change at commercial scale. Equally, an ingredient that is easy to source for development work can become a significant supply risk once annual demand increases. Neither issue reflects poor chemistry. Both reflect the reality of manufacturing at scale.

The businesses that recognise these challenges early are far better placed to solve them before they become expensive.

Why early decisions matter

The most successful products are not always the ones with the most innovative formulations. More often, they are the ones developed with commercial manufacture in mind from the outset. That means considering early on whether formulation can be produced reliably at volume, how sensitive it may be to normal process variation, whether raw material supply will remain secure as demand grows and whether packaging choices will support efficient filling, transport and end use.

It also means looking closely at whether the route from blending to finished product is as simple and resilient as it needs to be. These are not purely manufacturing considerations. They are commercial decisions that shape profitability, customer satisfaction and long-term growth.

The cost of discovering problems too late

When scale-up considerations are left until the final stages of development, even relatively small issues can become disproportionately expensive. By the time launch approaches, production schedules are committed, forecasts have been agreed, customers are waiting and commercial expectations are high.

At that point, a packaging bottleneck, inconsistent batch performance or a delay in raw material supply is no longer just an operational inconvenience. It affects launch dates, working capital, margins and, ultimately, customer confidence.

Scale doesn’t create these problems, but it does expose them. The question is whether they are identified during development, when they are relatively inexpensive to solve, or after launch, when the commercial consequences are much greater.

Why joined-up thinking matters

Over the years, one lesson has become consistently clear for us: the smoothest scale-up projects are rarely those with the most sophisticated formulations. They are the ones where formulation, manufacturing, supply planning and packaging have been considered together from the beginning.

As customer expectations continue to rise, businesses have less room for inconsistency. At the same time, supply chains remain under pressure, compliance requirements continue to evolve and many growing companies are expected to do more with leaner operational teams. In that environment, fragmentation becomes a genuine business risk.

If formulation sits with one partner, manufacturing with another, packing somewhere else and distribution elsewhere again, complexity often accumulates in the gaps. Information is lost during handovers. Problems take longer to resolve. Changes become harder to implement and accountability becomes less clear.

A more integrated approach doesn’t eliminate complexity, but it does make it easier to manage. When formulation knowledge, manufacturing expertise and production planning are connected, decisions can be made with a much clearer understanding of their downstream impact.

Scale without compromise

For specialist formulation and manufacturing partners, growth depends on being able to increase production without sacrificing consistency, quality or compliance. That requires technical expertise, but it also requires a different mindset.

Manufacturing should not be viewed as the final stage of development. It should be considered part of product strategy from the very beginning.

The businesses that scale most successfully understand that commercial success depends on far more than formulation performance alone. It is shaped by process design, supply resilience, packing decisions and operational capability just as much as by the chemistry itself.

From promising product to lasting success

Good products rarely fail because they lack technical potential.

More often, they fail because commercial reality exposes weaknesses that were never fully addressed while the stakes were lower.

Scale doesn’t reward good ideas on their own. It rewards businesses that build products – and the systems around those products – to perform consistently as demand grows.

That is the real opportunity for specialist formulation and manufacturing partners. Treating scale-up as a strategic discipline rather than a production milestone allows businesses to launch with greater confidence, respond more effectively to growth and build products that succeed not only in the laboratory, but in the marketplace.